Better Meat Co (BMC), a Sacramento-based startup, has successfully raised a $31 million Series A round, co-led by Future Ventures and Resilience Reserve. This funding will propel BMC to scale up production of its Rhiza mycoprotein, aiming to offer it at prices lower than US commodity ground beef by 2026. Noteworthy investors include Glenn Hickman from Hickman’s Family Farms, Epic Ventures, and Sigmas Group, among others.
The capital infusion will allow BMC to increase its patented tech production tenfold, from 9,000 to 90,000 liters. BMC has secured five signed LOIs from major meat companies, validating its products and strategy. Despite challenges faced by the alternative protein sector, including bankruptcies and shutdowns, BMC has stood resilient, avoiding layoffs and securing collaborations to sustain operations.
Rhiza mycoprotein, BMC’s flagship product, offers a meat-like experience with a fibrous texture, derived from Neurospora fungi species. Unlike plant-based alternatives, Rhiza requires minimal downstream processing and is considered a whole food ingredient. Meats enhanced with Rhiza boast superior yields, lower saturated fat, fewer calories, and increased fiber content, aligning with consumer trends towards healthier and sustainable food options.
BMC’s Rhiza mycoprotein has received regulatory approvals in Singapore, FDA’s GRAS status, and USDA approval for animal meat inclusion, marking a significant milestone in the mycoprotein space. The product’s efficient production process, 18-month shelf life, and room temperature stability make it a cost-effective and convenient ingredient for food manufacturers worldwide.
Future Ventures’ endorsement of BMC’s technology as a cost-effective and rapid solution in the alternative protein landscape highlights the company’s potential for long-term success. With the ability to go from start to final product in under 17 hours, BMC’s Rhiza mycoprotein demonstrates scalability, efficiency, and taste superiority compared to traditional meat sources, positioning it as a frontrunner in the protein alternatives market.
Key Takeaways:
- Better Meat Co’s $31 million Series A funding will drive the commercialization of its Rhiza mycoprotein, offering a more cost-effective and sustainable alternative to traditional meat sources.
- BMC’s resilient approach amidst industry challenges, regulatory approvals, and strategic collaborations underscore its potential for growth in the alternative protein sector.
- Rhiza mycoprotein’s unique attributes, including its meat-like texture, superior nutritional profile, and efficient production process, position it as a competitive player in the protein alternatives market.
- Future Ventures’ endorsement of BMC as a frontrunner in the alternative protein landscape validates the company’s innovation and scalability in meeting the growing demand for sustainable and healthy food options.
Tags: regulatory, downstream, biotech, fungi
Read more on agfundernews.com